Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massar Omar

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
American Heart Journal Plus : Cardiology Research and Practice|March 21, 2024
Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trialJulie Hempel Larsen, Massar Omar, Jesper Jensen, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 13, 2021
Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT)Manan Pareek, Muthiah Vaduganathan, Christina Byrne, et al.
Cardiovascular Diabetology|February 27, 2022
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)Massar Omar, Jesper Jensen, Caroline Kistorp, et al.
Circulation. Heart Failure|November 8, 2021
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical TrialMassar Omar, Jesper Jensen, Daniel Burkhoff, et al.
European Journal of Heart Failure|May 23, 2022
Sex and central obesity in heart failure with preserved ejection fractionHidemi Sorimachi, Kazunori Omote, Massar Omar, et al.
European Journal of Heart Failure|December 29, 2023
Clinical phenogroup diversity and multiplicity: Impact on mechanisms of exercise intolerance in heart failure with preserved ejection fractionKathryn Larson, Massar Omar, Hidemi Sorimachi, et al.
American Heart Journal|August 29, 2024
Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: Determinants and relationship with patient-reported health statusCamilla Fuchs Andersen, Massar Omar, Julie Hempel Larsen, et al.
Heart (British Cardiac Society)|November 10, 2022
Pressure-flow responses to exercise in aortic stenosis, mitral regurgitation and diastolic dysfunctionMads J Andersen, Emil Wolsk, Rine Bakkestrøm, et al.
JAMA Cardiology|January 6, 2021
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical TrialMassar Omar, Jesper Jensen, Mulham Ali, et al.
Journal of Clinical Lipidology|January 22, 2025
Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLEFrida Emanuelsson, Jesper Jensen, Massar Omar, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
American Heart Journal Plus : Cardiology Research and Practice|March 21, 2024
Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trialJulie Hempel Larsen, Massar Omar, Jesper Jensen, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 13, 2021
Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT)Manan Pareek, Muthiah Vaduganathan, Christina Byrne, et al.
Cardiovascular Diabetology|February 27, 2022
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)Massar Omar, Jesper Jensen, Caroline Kistorp, et al.
Circulation. Heart Failure|November 8, 2021
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical TrialMassar Omar, Jesper Jensen, Daniel Burkhoff, et al.
European Journal of Heart Failure|May 23, 2022
Sex and central obesity in heart failure with preserved ejection fractionHidemi Sorimachi, Kazunori Omote, Massar Omar, et al.
European Journal of Heart Failure|December 29, 2023
Clinical phenogroup diversity and multiplicity: Impact on mechanisms of exercise intolerance in heart failure with preserved ejection fractionKathryn Larson, Massar Omar, Hidemi Sorimachi, et al.
American Heart Journal|August 29, 2024
Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: Determinants and relationship with patient-reported health statusCamilla Fuchs Andersen, Massar Omar, Julie Hempel Larsen, et al.
Heart (British Cardiac Society)|November 10, 2022
Pressure-flow responses to exercise in aortic stenosis, mitral regurgitation and diastolic dysfunctionMads J Andersen, Emil Wolsk, Rine Bakkestrøm, et al.
JAMA Cardiology|January 6, 2021
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical TrialMassar Omar, Jesper Jensen, Mulham Ali, et al.
Journal of Clinical Lipidology|January 22, 2025
Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLEFrida Emanuelsson, Jesper Jensen, Massar Omar, et al.
Pageof 5